Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Coti (COTI) Holds Key Support — Could This Pattern Trigger an Upside Breakout?

Coti (COTI) Holds Key Support — Could This Pattern Trigger an Upside Breakout?

CoinsProbeCoinsProbe2025/11/06 10:39
By:Nilesh Hembade

Date: Thu, Nov 06, 2025 | 09:00 AM GMT

The cryptocurrency market is showing minor signs of relief after a sharp sell-off earlier this week that briefly pushed Bitcoin (BTC) to the $98K region before rebounding to $103K. This recovery is offering room for select altcoins to regain some green momentum — including COTI, the native token powering Coti’s privacy Layer 2 on Ethereum.

COTI is trading slightly higher today, though still down 41% over the past month. But despite this extended decline, its current technical structure suggests that the token could be approaching a potential bullish reversal phase.

Coti (COTI) Holds Key Support — Could This Pattern Trigger an Upside Breakout? image 0 Source: Coinmarketcap

Falling Wedge Pattern in Play

On the weekly chart, COTI is forming a falling wedge — a well-known bullish reversal pattern that typically forms during prolonged downtrends when selling pressure begins to weaken.

The latest correction pushed COTI down to the wedge’s lower boundary near $0.0251, a level that once again acted as strong support. From there, the token has rebounded to around $0.0277, indicating that buyers are stepping in to defend this zone.

Coti (COTI) Holds Key Support — Could This Pattern Trigger an Upside Breakout? image 1 Coti (COTI) Weekly Chart/Coinsprobe (Source: Tradingview)

This repeated defense of the wedge’s support trendline is a positive signal and could serve as the structural foundation for an upcoming reversal.

What’s Next for COTI?

If COTI continues to hold above the wedge’s lower trendline, the next key step would be a move toward the upper resistance line of the wedge. A successful breakout above this level would confirm a bullish reversal and could trigger a stronger upside recovery.

The primary technical target in such a scenario would be the 200-day Moving Average (MA) near $0.0927, which stands as a major resistance and trend confirmation level.

However, traders should monitor the wedge support closely. A breakdown below the lower trendline could invalidate the bullish setup and expose COTI to deeper downside before any meaningful rebound takes shape.

For now, the chart leans cautiously optimistic — the falling wedge remains intact, and buyers are showing signs of defending key support.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23

Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market

Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.

智通财经•2026/11/06 12:37
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market